Cognis acquires interest in InterMed Discovery
Global speciality chemicals company Cognis has acquired an interest in InterMed Discovery, of Dortmund in Germany, and at the same time signed a co-operation agreement.
Global speciality chemicals company Cognis has acquired an interest in InterMed Discovery, of Dortmund in Germany, and at the same time signed a co-operation agreement.
The deal allows Cognis to strengthen its portfolio of natural source products and gives it access to one of the world's largest natural product databases and exclusive access to selected potential active ingredients for specific applications.
InterMed Discovery researches and develops active ingredients based on natural products. The company owns one of the world's largest proprietary collections of biologically active natural substances and extracts. Using its unique technology platform, InterMed Discovery can correlate chemical structures with biological activity on a large scale (IMD Bioprofiling) and thus identify novel active ingredients with defined applications.
Together with InterMed Discovery Cognis will utilise this database and technology to select, develop and market suitable active substances exclusively.
"The combination of InterMed Discovery's natural product data and active ingredients with Cognis" know-how and market expertise creates a unique platform for the development of new, innovative products and thus strengthens our market position sustainably," said Norbert Weitkemper, director strategic business development nutrition & health at Cognis.
InterMed Discovery was founded in 2006 as a management buy-out from Bayer HealthCare. The company provides innovative, functional natural products for applications in all areas of the life sciences. In addition to focusing on the development of its own active compound portfolio, InterMed Discovery also performs natural product research and provides strategic co-operations.